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ABSTRACT 
Cholangiocarcinoma (CCA) is a heterogeneous disease arising from a complex interaction 
between host-specific genetic background and multiple risk factors. Globally, CCA incidence 
rates exhibit geographical variation, with much higher incidence in parts of the Eastern world 
compared to the West. These differences are likely to reflect differences in geographical risk 
factors as well as genetic determinants. Of note, over the past few decades, the incidence 
rates of CCA appear to change and subtypes of CCA appear to show distinct epidemiological 
trends. These trends need to be interpreted with caution given the issues of diagnosis, 
recording and coding of sub-types of CCA. Epidemiological evidences suggest that in general 
population some risk factors are less frequent but associated with a higher CCA risk, while 
others are more common but associated with a lower risk. Moreover, while some risk factors 
are shared by intrahepatic and both extrahepatic forms, others seem more specific for one of 
the two forms. Currently some pathological conditions have been clearly associated with 
CCA development, and other conditions are emerging; however, while their impact in 
increasing CCA risk as single etiologic factors has been provided in many studies, less is 
known when two or more risk factors co-occur in the same patient. Moreover, despite the 
advancements in the knowledge of CCA aetiology, in Western countries about 50% of cases 
are still diagnosed without any identifiable risk factor. It is therefore conceivable that other 
still undefined etiologic factors are responsible for the recent increase of CCA (especially 
iCCA) incidence worldwide. 

clinical presentations, management and prognoses,3 subtypes of CCA also appear to show 
distinct epidemiological trends. 
Evolving epidemiology of Cholangiocarcinoma 
Multiple studies have shown rising rates of iCCA. This was first reported in the United 
Kingdom, where a 15-fold increase in age specific mortality rates for iCCA in ages 45 and 
above was found between 1968 and 1996.7 There was a steady decrease in extrahepatic CCA 
over the same period.7 Further studies published in the early 2000’s showed similar findings, 
i.e. rising iCCA and falling extrahepatic CCA in both genders across many European 
countries, the US, Australia and Japan.2,8 More recent studies report these patterns are 
continuing. Bertuccio et al. used data from the World Health Organization (WHO) to 
compute age-standardized (world population) mortality rates in primary liver cancer (PLC) 
and employed join-point analysis to identify substantial changes.9 Between 2002 and 2007, 
PLC rates across 12 selected European Union (EU) countries overall declined from 3.9 to 
3.6/100,000 in men. In women, mortality was lower (0.8/100,000 in 2007 in the EU), and 
showed more favourable trends, with a decline of over 2% per year over the last two decades 
as compared with 0.4% in men. In contrast, mortality from iCCA increased by around 9% in 
both sexes from 1990 to 2008, reaching rates of 1.1/100,000 men and 0.75/100,000 women, 
the highest rates occurring in the United Kingdom (UK), Germany, and France.9 Data for the 
United States, Japan, and Australia was also analysed for comparison, and similar trends were 
found.9
A recent US study analysed Surveillance, Epidemiology, and End Results data to assess 40-
year trends in the age-standardized incidence of intrahepatic and extrahepatic CCA between 
1973 and 2012.10 As iCCA may potentially be misdiagnosed as cancer of unknown primary 
(CUP), trends in the incidence of CUP were also analysed.  Between 1973 and 2012, the 
reported U.S. incidence of iCCA increased from 0.44/100,000 to 1.18/100,000, representing 
an annual percentage change (APC) of 2.30%. This trend accelerated during the last decade 
to an APC of 4.36%; whereas the incidence of extrahepatic CCA increased modestly from 
0.95/100,00 to 1.02/100,000 during the 40-year period (APC, 0.14%). The incidence of CUP 
with histologic features potentially consistent with cholangiocarcinoma decreased by 51% 
between 1973 and 2012 (APC, -1.87%). Thus, although the incidence of iCCA in the U.S. 
rose, the incidence of CUP fell during the same period.10 In a phase II trial of patients with 
previously untreated CUP, molecular tumour profiling enabled determination of the tissue of 
origin in 98% of cases. Of 289 patients, 18% were found to have biliary tract cancer.11 Hence, 
the improved clinical distinction between CUP and iCCA might be another factor 
contributing to the apparent increase in iCCA incidence.10 
However, other single nation studies reported different CCA incidence trends. The incidence 
of both intra- and extrahepatic CCA remained stable in Burgundy, France,12 and iCCA 
incidence reportedly actually decreased in Denmark over recent decades.13 Furthermore, data 
from the North American Association of Central Cancer Registries indicate that the incidence 
of iCCA fell between 1998 and 2003 ([APC -8% per year), then rose between 2003 and 2009 
(APC 6% per year); the incidence of extrahepatic CCA increased between 1998 and 2003 
(APC 9% per year), before plateauing from 2003 to 2009.14 
CCA Coding and Misclassification 
The reasons for these changes in trends in CCA are unclear. iCCA is a primary liver cancer 
and shares several similar underlying risk factors with HCC.4 Several of these risk factors are 
also known to be increasing globally and are discussed in detail below. Improvements in the 
accuracy and availability of diagnostic tools over the past few decades may also have 
contributed to diverging incidence rates of various hepatobiliary malignancies, but it is 
exceptionally difficult to measure this effect.15 
Another important issue that requires consideration when interpreting reported 
epidemiological trends in CCA is the ever evolving WHO International Classification of 
Disease (ICD) coding system, which is used by cancer registries internationally to record 
different cancers and thus feeds into national datasets which are analysed in published 
studies. Multi-disciplinary specialists involved in CCA clinical care and research generally 
agree that CCA should be divided into three distinct sub-types: iCCA, pCCA, and 
distal/extrahepatic (dCCA), as these three sub-types have distinct epidemiology, biology, 
prognosis and clinical management approaches.1,3,16 Although pCCA (historically often 
referred to as “Klatskin” tumours) make up the bulk of CCA, unfortunately, to date no 
version of the ICD coding system distinguishes between pCCA and dCCA. The main form of 
ICD has codes for all known diagnoses, cancer and non-cancer, and the current version in use 
at the time of writing is ICD-10. ICD-10 lists topography codes, which describe the 
anatomical site of origin, or organ, of a tumour. A separate ICD exists for cancers only, ICD-
Oncology (ICD-O), overseen by the International Agency for Research on Cancer (IARC), 
the specialized cancer agency of the WHO. ICD-O-3, the third iteration of ICD-O, is 
currently in use and consists of two coding systems, which together describe the tumour: 1) 
the topographical code, which describes the anatomical site of origin (or organ system) of the 
tumour, and 2) the morphological code, which describes the cell type (or histology) of the 
tumour, together with the behaviour (malignant or benign). ICD-10 (and previous versions of 
ICD) have separate topography codes for iCCA (C22.1) and dCCA (C24.0), but none for 
pCCA. ICD-O also has no topographical code for pCCA. However, ICD-O has a 
morphological code for pCCA, but does not have specific morphological codes for iCCA or 
dCCA. Thus, although multiple studies report rising incidence rates of iCCA and falling rates 
of extrahepatic CCA, we do not know what is happening with incidence/mortality rates of 
pCCA, the commonest form of CCA, which could have been incorrectly coded as either 
iCCA or dCCA in current and previous versions of ICD coding.17 
Furthermore, ICD and ICD-O editions change every few years, but are adopted by different 
countries at different times, which again could potentially contribute to differences between 
countries’ reported rates. The second edition of the ICD-O (ICD-O-2) assigned ‘Klatskin’ 
tumours (pCCA) a unique histology code, but this was cross-referenced to the topography 
code for intrahepatic rather than extrahepatic CCA.17 With the advent of ICD-O-3, however, 
‘Klatskin’ tumours can be cross-referenced to either intrahepatic or extrahepatic 
cholangiocarcinoma. A study of UK data and US Surveillance, Epidemiology, and End 
Results (SEER) data examined whether a change in ICD-O coincided with changes in 
recorded rates of different types of CCA.17. In the USA, the switch from ICD-O-2 to ICD-O-
3 occurred in 2001, whereas in the UK, this switch did not occur until 2008.17 Age-
standardised incidence rates (ASIR) in England and Wales between 1990 and 2008 markedly 
increased for iCCA and decreased for pCCA/dCCA. This trend was still evident after 
transferring all CCA recorded as “Klatskin” from intrahepatic to extrahepatic codes.17 
Remarkable however, only 1% of all CCA were reportedly Klatskin, which cannot be a true 
reflection of all pCCA cases. Of note, on direct questioning, most UK cancer registries 
reported that if a tumour site is unspecified, most would classify CCA as intrahepatic.17 The 
analysis of US SEER data found that ASIR of iCCA rose from 0.6 per 100,000 individuals in 
1990 to 0.9 per 100,000 individuals in 2001. But from 2001, when ICD-O-3 was adopted in 
the US, the ASIRs for iCCA began to decrease, before plateauing at 0.6 per 100,000 
individuals by 2007. Conversely, ASIRs for pCCA/dCCA remained stable at around 0.8 per 
100,000 individuals until 2001, and then began increasing, reaching 1.0 per 100,000 
individuals by 2007.17 Other studies have highlighted the potential for misclassification of 
CCA.18,19 Systematic under-reporting of the incidence of CCA may be another confounding 
issue. This was noted in a study of the concordance between Swedish cancer registries and 
patient registries, which found that between 1990 and 2009, 44% of CCA were reported only 
in the patient registries.20 
In conclusion, potential explanations behind the trends in CCA incidence are complex and 
reported changes in incidence rates need to be interpreted with caution. For example, it is 
quite possible that pCCA, the most-common subtype of CCA, is regularly being misclassified 
as iCCA, the least common subtype, thereby falsely skewing the reported rates of iCCA. 
Going forward, diagnoses and epidemiological data need to be recorded uniformly and 
accurately. This responsibility resides with both clinicians and cancer registries, as well as 
with ICD coding system, which needs to more accurately reflect the different types of CCA. 
There is a need for both ICD-11 and subsequent iterations of ICD-O to have separate 
topography and morphology codes for iCCA, pCCA and dCCA. 
RISK FACTORS 
Cholangiocarcinoma: a heterogeneous disease arising from multiple risk factors 
CCA encompasses an assorted group of malignancies lacking a stereotyped phenotype and 
molecular signature.1,3,4  Compelling evidence supports the notion that CCA heterogeneity is 
the result of a complex interaction between the host-specific genetic background and a 
different geographical distribution of the risk factors (Table 2) associated with this disease. 
Epidemiological studies suggest that multiple risk factors are involved in 
cholangiocarcinogenesis, and that some of them are less frequent but associated with a higher 
risk of CCA, whereas others are more common but associated with a lower risk. Moreover, 
while some risk factors seem to be shared by iCCA and the two extrahepatic forms (hereafter 
referred to eCCA), others seem more specific for iCCA or eCCAs.21 This last observation is 
also reinforced by the broad geographic variations in iCCA and eCCA incidence, a 
phenomenon that suggests a spatial-temporal segregation of the underlying etiologic factors. 
The existence along the biliary tree of two distinct stem cell niches (the canals of Hering and 
the peribiliary glands) susceptible to different injuries may add a further level of complexity 
in the identification of the risk factors linked to CCA.22 
Currently, some pathological conditions have been clearly linked to CCA development, and 
other conditions are emerging from recent studies. However, while their impact as single 
agents in increase CCA risk has been established, less clear is when two or more risk factors 
co-occur in the same patient. Moreover, despite the advancements in the knowledge of CCA 
aetiology, in Western countries about 50% of cases are still diagnosed without any 
identifiable risk factor. It is therefore conceivable that other still undefined factors are 
responsible for the recent reported increases in CCA (especially iCCA) incidence worldwide, 
a phenomenon that justifies the increasing scientific attention towards this disease. 
Cholangiocarcinoma misclassification and possible biases on risk factor aetiology 
CCA incidence shows wide geographic differences worldwide.1 However, while these 
differences are expected among populations exposed to different risk factors, epidemiological 
discrepancies observed among populations exposed to similar risk factors are less expected. 
Likely, such discrepancies rely not only on possible errors in cancer registers, but also on 
misclassification of some CCA forms. Indeed, some iCCAs may be misdiagnosed as CUP, 
HCC or mixed HCC-iCCA, whereas some Klatskin tumors can be topographically ascribable 
to iCCA or eCCA;18 moreover, the diagnosis of CCA at an advanced stage makes sometimes 
difficult to identify its anatomical origin. 
In this scenario, as CCA still remains a relatively rare cancer, misclassification can introduce 
significant biases in the identification of the risk factors associated with this disease. A more 
refined CCA classification, along with an accurate diagnosis and patient anamnesis, is 
therefore required to better clarify the underlying aetiology of this disease. 
Bile duct disorders 
• Bile duct cysts
Bile duct cysts are a rare congenital disorder characterized by cystic dilatation of the 
intrahepatic and/or extrahepatic biliary tree; according to the classification, they can be 
divided into type I, type II, type III, type IV and type V (Table 3).23 The frequency of bile 
duct cysts is high in females of Asian countries, especially China and Japan, while is 
relatively low in Western populations.24 The association between bile duct cysts and CCA is 
well established and, when they are undetected or treated inappropriately, tumour can arise 
from both cysts and undilated parts of the biliary tree.25 A recent analysis based on the US 
SEER registry reported an odds ratio (OR)=15.66 (95% confidence interval [CI ]11.58–
21.18) for iCCA and an OR=27.12 (95% CI 22.06–33.34) for extrahepatic CCA (eCCA).26 
Typically, these patients develop CCA at a mean age of 32 years (much lower than in the 
general population), and the higher incidence has been documented among subjects with type 
I and IV bile duct cysts.27 Surgical treatment usually decreases the risk of CCA in these 
patients; however, also after surgery such risk remains higher than the general population.28 
Reflux of pancreatic enzymes, bile stasis and increased intraductal concentration of bile acids 
may contribute to malignant transformation of the epithelium lining the cystic bile duct 
wall.27 According to preliminary findings, bacterial infection could also play a role in CCA 
development in patients with bile duct cysts.29 
Caroli's disease is a rare autosomal recessive disorder characterized by non-obstructive gross 
dilatation of the segmental intrahepatic bile ducts and has been included in the classification 
of type V choledochal cysts. The associated bile stasis, chronic inflammation and cholangitis 
have been suggested as conditions linked to the increased cancer risk in these patients.30 
Caroli’s diseases has been reported as one of the strongest risk factors for both iCCA and 
eCCA, conferring a 38-fold higher risk for iCCA (OR=38.13, 95% CI 14.20–102.38) and a 
97-fold higher risk for eCCA (OR=96.81, 95% CI 51.02–183,68).26 The risk of malignant
transformation associated with Caroli’s diseases mostly occurs after the second decade of
life, although some cases have been reported among teenagers.31
• Primary sclerosing cholangitis/cholangitis
Primary sclerosing cholangitis (PSC) is an autoimmune disease affecting bile ducts, leading 
to inflammation and subsequent obstruction of both intra- and extrahepatic bile ducts. 
Patients with PSC carry a 400-fold higher risk for CCA than the general population 
(standardized incidence rate, 398, 95% CI 246-608), with a reported overall incidence of 
about 7%.32 In these patients, CCA is usually diagnosed in the fourth decade of life compared 
to the seventh decade in general population, and longitudinal studies have shown that up to 
50% of CCAs are detected within the first year of PSC diagnosis.21 Results from the US 
SEER registry also reported a strong association between cholangitis and CCA development, 
with an OR=21.52 (95% CI 7.21–26.90) for iCCA and an OR=40.80 (95% CI 34.96–47.60) 
for eCCA.26 However, this analysis did not distinguish the impact of the autoimmune forms 
from that arising from the others forms of cholangitis.  
The causal link between PSC/cholangitis and CCA development likely includes chronic 
inflammation, proliferation of biliary epithelium, production of endogenous bile mutagens 
and bile stasis.21,33 The presence of some inflammatory conditions, such as inflammatory 
bowel disease (IBD), have been reported in some studies to significantly increase the risk of 
CCA in PSC, compared to non-PSC-IBD subjects (Hazard ratio, HR= 190, 95% CI 54.8-
660), with the highest incidence of CCA occurring within the first year after diagnosis of 
IBD.34,35 However, no additional risk of CCA in PSC patients was reported in a US study.36 
Therefore, the impact of IBD in increasing the risk of CCA in PSC patients remains to be 
fully clarified. 
• Hepatolithiasis, cholelithiasis and choledocholithiasis
Hepatolithiasis refers to the presence of calculi in the intrahepatic biliary tree. This condition 
is rare in Western Countries (0.6-1.3%), while fairly common in the East Asia (up to 25%).37 
In patients with hepatolithiasis, the association with iCCA has been well documented, with an 
overall incidence of 5-13%.37,38 Hepatolithiasis has been found to represent a strong risk 
factor for iCCA in a Korean case-control study (OR = 50.0, 95% CI 21.2–117.3).39 The role 
of hepatolithiasis in the genesis of iCCA has been also confirmed outside Asia; an OR=6.7 
(95% CI 1.3–33.4) was indeed observed in an Italian case-control study.40 The association 
between hepatolithiasis and iCCA is likely linked to chronic inflammation, bile stasis and 
bacterial infections.37 Concurrence of hepatolithiasis and parasitic infestations has been 
documented in Asia;41 in addition, smoking, family history of cancer and duration of 
symptoms longer than 10 years have been suggested as risk factors for iCCA in patients with 
hepatolithiasis.42 
Cholelithiasis and choledocholithiasis are both conditions that have been linked to increased 
risk for eCCA and the risk seems to increase with gallstones size, epithelium calcification and 
disease duration.43 Conversely, their role in iCCA pathogenesis is less clear. A recent analysis 
based on the US SEER registry reported a significant association between CCA development 
and cholelithiasis/choledocholithiasis; this association was stronger for eCCA (cholelithiasis: 
OR=5.29, 95% CI 4.83-5.80; choledocholithiasis: OR=14.22, 95% CI 12.48-16.20) than for 
iCCA (cholelithiasis: OR=3.93, 95% CI 3.49-4.43; choledocholithiasis: OR=6.94, 95%CI 
5.64-8.54).26 In addition, a meta-analysis of seven case-control studies suggested that 
choledocholithiasis without hepatolithiasis associates with a high risk of iCCA, whereas the 
evidence for cholelithiasis seems less clear.44 
Liver diseases  
• Cirrhosis
Liver cirrhosis is a manifestation of advanced liver disease. In cirrhotic livers, the 
architecture of hepatic parenchyma is subverted by fibrosis and regenerative nodules that 
determine progressive loss of liver function. Cirrhosis is a well-established risk factor for 
HCC, with > 90% of HCCs developing in cirrhotic patients.45 In a meta-analysis from seven 
case-control studies, liver cirrhosis was also identified as a strong risk factor for iCCA 
(OR=22.92, 95% CI 18.24–28.79).46 Cirrhosis might also represent a risk factor for eCCA; an 
OR=5.4 (95% CI 2.9–10.2) was indeed estimated in a large case-control study conducted in 
the US population.47 A recently population-based case-control study in Asian patients also 
reported an increased risk for iCCA (OR=8.0, 95% CI 6.6–9.8) and eCCA (OR= 3.9, 95% CI: 
3.0–5.1) in cirrhotic patients.48 The raised risk of iCCA and, possibly, eCCA, in cirrhotic 
patients could be explained by the increased cellular proliferation, release of inflammatory 
cytokines and occurrence of fibrosis in the liver.49 
• Viral Hepatitis
Hepatitis B (HBV) and C (HCV) virus chronic infection is a strong risk factor for HCC. 
Findings from different epidemiological studies suggest that these infections may also 
represent a risk factor for CCA development, with a stronger association for iCCA.50 The 
association between hepatitis viruses and iCCA incidence was found to vary between 
Western and Asian countries. Indeed, while in Western populations iCCA was stronger 
associated with HCV, in Asian populations this malignancy was stronger associated with 
HBV, where this infection is endemic.46,51,52 According to a meta-analysis including 16 case-
control and 2 cohort studies, the risk of iCCA in patients with HBV infection was more than 
three times higher than in patients without HBV infection (relative risk, RR=3.42, 95% CI 
2.46–4,74).53  The meta-analysis also identified signs of a small increase in eCCA risk 
(RR=1.46, 95% CI 0.98–2.17).53 The association between HBV and iCCA has been also 
confirmed in another study, where an OR=5.10 (95% CI 2.91–8.95) was reported.52 More 
recently, a meta-analysis including thirty-nine studies reported an OR=2.72 (95% CI 1.90–
3.88) for the risk of CCA in HBV positive patients; in particular, an OR=3.184 (95% CI 
2.356–4.302) was found for iCCA, whereas a weak association was found for eCCA (OR= 
1.407, 95% CI 0.925–2.141).54  
An OR=4.84 (95% CI 2.41–9.71) was estimated in a meta-analysis of eight case-control 
studies evaluating the association between HCV and iCCA.46 In another meta-analysis of 
sixteen case-control studies, pooled risk estimates showed a significant increased risk for 
CCA in HCV positive patients (OR= 5.44, 95% CI, 2.72-10.89); notably, the pooled risk 
estimate of iCCA was higher than eCCA (OR=3.38, 95% CI, 2.72-4.21 vs OR=1.75, 95% CI, 
1.00-3.05).55 The presence of liver cirrhosis in HBV or HCV patients was shown to increase 
the risk of CCA; in particular, the risk of iCCA was found to increase 2.5-fold (95% CI 1.2-
5.1) in HBV positive patients and 3.2-fold (95% CI 1.2-8.1) in HCV positive patients.56 The 
increased risk of CCA among HBV and HCV patients likely relies not only on the presence 
of liver cirrhosis, but also on a direct carcinogenic effect by these viruses on target cells;57 
moreover, chronic liver inflammation resulting from virus infection triggers cellular 
proliferation, thus increasing the risk of malignant transformation.57 
• Hemochromatosis
Hemochromatosis type 1 is a genetic disorder most commonly linked to the 
HFE1 mutation (C282Y) and is characterized by pathological iron accumulation in the body, 
particularly in the liver. Clinical manifestations include cirrhosis, polyarthropathy, adrenal 
insufficiency, heart failure or diabetes.58 While hemochromatosis has been clearly reported to 
increase the HCC risk,59 a definitive conclusion about its role in CCA cannot be yet provided. 
Some case reports and case series suggest an association between hemochromatosis and 
iCCA development.60-63 Results from the US SEER registry reported an OR=2.07 (95% CI 
1.33-3.22) for iCCA, whereas no increased risk was found for eCCA.26 This last finding is 
not totally surprising, as iron deposition preferentially occurs in the liver. Liver cirrhosis, a 
common clinical manifestation of hemochromatosis, could explain the increased iCCA risk. 
However, some iCCA cases have been also observed in hemochromatosis patients without 
cirrhosis, suggesting that hemochromatosis could increase the iCCA risk independently from 
this disease.64,65 The hypothesized molecular mechanisms linking hemochromatosis to iCCA 
are similar to those observed for HCC and include formation of reactive oxygen 
species (ROS) within the liver, DNA damage, lipid peroxidation and acceleration 
of fibrogenesis.66 Indeed both HCC and iCCA arise from the differentiation of common 
hepatic progenitor cells localized in the canals of Hering, and activation of this stem cell 
compartment typically occurs in chronic liver diseases.67  
 
• Wilson’s disease
Wilson's disease is an autosomal recessive hereditary disorder due to mutations in the Wilson 
disease (ATP7B) gene and is characterized by copper accumulation in several tissues, 
primarily liver, brain and other vital organs.68 A recent cohort study on 1186 patients showed 
that sporadic cases of iCCA (0.5%) occurred in patients with Wilson's disease.69 The reason 
for these low incidences is still debated. Indeed, while an excess of copper is known to induce 
DNA damage via ROS generation,70 a protective role of this metal against malignancies has 
been also reported in some studies.71-73  
Digestive diseases 
• Inflammatory bowel disease
Inflammatory bowel disease is a known risk factor for colorectal cancer.74,75 According to a
recent meta-analysis, an increased CCA risk was reported in IBD patients (RR=2.63, 95% CI
= 1.47-4.72).36 Site-specific analyses revealed a RR= 2.61 (95% CI 1.72-3.95) for iCCA,
whereas a RR= 1.47 (95% CI 1.10-1.97) for eCCA.36 Both ulcerative colitis and
Crohn's disease were found to be associated with increased CCA risk, although a stronger
association was found for ulcerative colitis (RR= 3.40, 95% CI 2.50-4.62 vs RR=2.69, 95%CI
1.59-4.55, respectively).36 A recent analysis based on the US SEER registry also confirmed a
stronger association with iCCA for ulcerative colitis (OR=2.18, 95% CI 1.61-2.95) compared
to Crohn's disease (OR=1.77, 95% CI 1.13-2.75), whereas a similar increased risk was found
for eCCA (OR=1.75, 95% CI 1.32-2.33 vs OR=1.71, 95% CI 1.17-2.51).26 Both pathological
conditions may be related to CCA development by induction of chronic inflammation and/or
microbiome dysbiosis.76 IBD may also have extra-intestinal manifestations, including PSC, a
well-known risk factor for CCA.77 In a retrospective cohort study based on
Danish national registries, the co-existence of IBD was reported to significantly increase
CCA risk in PSC patients (HR=190, 95% CI 54.8-660), compared to subjects with no PSC
and IBD;35 conversely, in a US study neither IBD nor its duration conferred additional CCA
risk in PSC patients.36 Therefore, the impact of IBD in increasing the CCA risk in PSC
patients remains undefined.
• Chronic pancreatitis and duodenal/gastric ulcer
A positive association between chronic pancreatitis and CCA has been reported, with a 
stronger association for eCCA (OR:=6.61, 95% CI 5.21-8.40) than iCCA (OR=2.66, 95% CI 
1.72-4.10).26 About 3–23% of patients with chronic pancreatitis develop biliary stricture, 
which in turn may lead to cholangitis and cholelithiasis, both representing well known risk 
factors for CCA.78 
A modest association between duodenal/gastric ulcer with Helicobacter Pylori (H. Pylori) 
infection and CCA has been reported, either for iCCA (OR=1.42, 95% CI 1.21-1.66) or 
eCCA (OR=1.46, 95%CI 1.29-1.66).26 It has been hypothesized that H. pylori may play a 
role in cholangiocarcinogenesis by increasing the cell kinetics of the biliary epithelium and 
inducing the formation of stones.79 A meta-analysis of ten case-control studies suggests that 
other Helicobacter species may be also involved in CCA development (cumulative OR=8.88, 
95%CI 3.67-21.49);80 however, since CCA patients (especially those with eCCA) often 
undergo endoscopy, these findings should be interpreted with caution. 
Parasitic infections 
O. viverrini and C. sinensis liver flukes have been identified as strong risk factors for CCA, 
and in endemic areas of Eastern Asia the vast majority of CCAs are linked to these parasitic 
infestations.81 It has been estimated that up to 10% of people chronically infected with these 
liver flukes will develop CCA, especially iCCA.82 A meta-analysis of case-control studies 
reported a strong association between O. viverrini and C. sinensis infections and CCA 
(OR=4.8, 95% CI 2.8-8.4).83 O. viverrini and C. sinensis are flat worms that colonize the bile 
ducts and infestation in humans typically occurs via the ingestion of raw, pickled, or 
undercooked fish. O. viverrini has been classified as ‘‘carcinogenic to humans’’ by IARC 
more than twenty years ago due to its role in the development of CCA.84 More recently, the 
same definition was extended also to C. sinensis.85 Infection with these parasites may lead to 
CCA by inducing chronic inflammation, cholangitis and fibrosis of the periportal system over 
the course of decades.86 Despite anti-helminthic treatment, multiple reinfections are common 
and tend to be chronic, a phenomenon that may contribute to cholangiocarcinogenesis 
particularly when exposure to other genetic, environmental and infective factors coexists.87,88 
Metabolic and endocrine disorders 
• Type II diabetes
In the last years, epidemiological studies have provided evidences that some metabolic 
disorders may predispose to primary liver cancers.89 A meta-analysis of ten case-control 
studies and five cohort studies found a positive association between type II diabetes and 
iCCA (RR 1.97, 95% CI 1.57–2.46), as well as eCCA (RR 1.6, 95% CI 1.29–2.05).90 A 
positive association between type II diabetes and both CCA cancer types, especially iCCA, 
has been also reported in a more recent population-based study, where an OR=1.54 (95% CI 
1.41-1.68) was observed for iCCA and an OR=1.45 (95% CI 1.34-1.56) for eCCA.26 Diabetic 
patients who received metformin had a lower risk to develop iCCA (OR=0.4, 95% CI 0.2–
0.9), compared to diabetic patients not treated with metformin, thus reinforcing the potential 
link between diabetes and iCCA risk.91 Whether the potential association between diabetes 
and CCA may be direct or mediated by other intermediate risk factors, such as obesity or 
non-alcoholic fatty liver disease (NAFLD), remains unclear. Type II diabetes is characterized 
by compensatory hyperinsulinemia, and insulin has been shown to stimulate cancer cell 
growth by binding to insulin receptors. Furthermore, diabetes may increase the risk of biliary 
stones, an independent risk factor for eCCA.90 
Obesity 
The role of obesity in CCA development is still controversial and current evidence is too 
limited to make any solid conclusions.92 However, a meta-analysis of three case-control 
studies showed a pooled OR=1.56 (95% CI 1.26–1.94) for iCCA.46 A positive association 
between obesity and CCA has been also reported in another meta-analysis including five 
cohort and five case-control studies where, compared to normal weight subjects, a pooled 
OR=1.52 (95% CI 1.13-1.89) was found in obese subjects. However, the analysis was not 
stratified according to tumor location.93 These findings are consistent with current knowledge 
supporting an increased risk for many cancers with obesity. Obesity could increase the risk of 
cancer, including CCA, by affecting the levels of leptin, adiponectin and proinflammatory 
cytokines.92 
NAFLD/NASH  
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases ranging 
from fatty liver to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD/NASH has 
been identified as a risk factor for different cancer types, especially HCC;94,95 however, few 
studies have investigated the possible involvement on CCA pathogenesis. A population-based 
study reported that NAFLD was associated with an increased risk of iCCA (OR= 3.52, 95% 
CI 2.87-4.32) and eCCA (OR= 2.93, 95% CI 2.42-3.55).26 A positive association between 
NAFLD and CCA has been also suggested from a recent meta-analysis of seven case-control 
studies (pooled OR=1.95, 95%CI 1.36–2.79).96 When classified according to CCA subtypes, 
NAFLD was stronger associated with iCCA (OR= 2.22, 95% CI 1.52–3.24) than eCCA 
(OR=1.55, 95% CI 1.03–2.33), suggesting that iCCA and HCC may share a common patho-
genetic mechanism.96 It is biologically conceivable that NAFLD may promote CCA 
development directly by induction of hepatic inflammation or, indirectly, via cirrhosis. A 
cohort study reported that NASH affected up to 20% of patients with iCCA. Notably, these 
patients were more likely obese (median body mass index 30.0 vs 26.0 kg/m2) and had higher 
rates of diabetes mellitus (38.7 vs 22.0 %), compared to those ones without NASH.97 More 
recently, Kinoshita et al. showed that NASH is an independent risk factor for iCCA 
(OR=3.36, 95% Cl 1.15-10.2).98 Overall these findings suggest that NAFLD/NASH may 
represent a risk factor for iCCA. Nonetheless, further studies are warranted to better elucidate 
the strength of the association and the mechanisms underlying this relationship. Moreover, 
while a role for NASH, obesity and type II diabetes in increasing CCA risk as single etiologic 
factors has been provided in some studies, the relative impact of these overlapping diseases in 
increasing CCA risk when they co-occur in the same patient still remains an open question 
due to the lack of data. 
Life style 
• Alcohol consumption
Alcohol consumption has been clearly established as a risk factor for HCC;99 conversely, its
association with iCCA has been less investigated. A meta-analysis including eleven case-
control studies reported that heavy alcohol consumption (about six drinks/day) associates
with increased risk of iCCA (OR=2.81, 95% CI 1.52-5.21).46 
 Similarly, results from the Liver Cancer Pooling Project (including 14 US-based prospective 
cohort studies) showed that, compared to non-drinkers, heavy alcohol consumption (≥5 
drinks/day) was associated to a 68% increased risk of iCCA (HR= 1.68, 95% CI 0.99–
2.86).100 Another prospective cohort study in Japan reported a HR=1.96 (95% CI 0.99–3.91) 
for iCCA in regular drinkers consuming ≥300 g/day of ethanol, compared to non-drinkers; 
however, these results did not reach statistical significance (p-trend = 0.065), probably 
because of the small number of iCCA cases included.101 Whether the association between 
alcohol consumption and iCCA is related to liver disease (i.e. alcoholic liver disease and 
cirrhosis), or to other underlying carcinogenic mechanisms is unclear. Indeed, alcohol may 
contribute to carcinogenesis by induction of CYP2E1, which metabolises ethanol to 
acetaldehyde, increasing reactive oxygen-species production, lipid peroxidation and DNA 
damage. In addition, ethanol may induce enzymes that metabolize pro-carcinogens to 
carcinogens.102 
As to eCCA, a meta-analysis including eleven case-control studies and one cohort study 
reported a similar risk between regular drinkers and non-drinkers (summary RR=1.09, 95% 
CI 0.87-1.37).103 The lack of association between alcohol consumption and eCCA could rely 
on the protective effects of alcohol against gallstone formation (a well-known risk factor for 
eCCA) by inhibition of cholesterol metabolism.104 
• Cigarette smoking
Cigarette smoking has been investigated as a risk factor for CCA. A meta-analysis of case-
control studies conducted in 2012 showed marginal evidence of association between smoking 
and iCCA (OR 1.31, 95% CI 0.95–1.82). However, there was high heterogeneity among the 
studies included.46 More recently, two different studies reported a positive association 
between smoking and iCCA (HR=1.47, 95% CI 1.07–2.02 and OR=1.46, 95% CI 1.28-1.66, 
respectively).26,100 A meta-analysis of eleven case-control studies reported an increased risk 
also for eCCA in smokers, compared to non-smokers (summary RR =1.23; 95% C 1.01-
1.50).103 Similarly, an analysis based on the US SEER registry reported a 77% increased risk 
of eCCA in smokers (OR 1.77, 95% CI 1.59-1.96) compared to non-smokers.26 Early studies 
suggest that tobacco may exert carcinogenic effects on biliary epithelial cells since 
carcinogenic compounds (e.g. benzopyrene, formaldehyde, benzene and chromium) are 
metabolized by hepatic microsomes and excreted to bile.105,106 However, the causal role of 




Epidemiological studies suggest a positive association between CCA and exposure to some 
environmental carcinogens, with varying strength of evidence. A three-hundred-fold increase 
in CCA risk has been reported in subjects exposed to the radiographic contrast agent 
Thorotrast, due to the emission of alpha-radiations;107,108 however, as this compound has been 
banned since 1969, the number of CCAs currently linked to exposure to thorotrast is 
negligible. 
Chronic exposure to 1,2-dichloropropane, an organic solvent used in printing, has been also 
implicated as a causative factor for CCA in a recent study (adjusted RR=14.9, 95%CI 4.1-
54.3 for middle exposure category and adjusted RR=17.1, 95% CI 3.8-76.2 for high exposure 
category).109 
Several cohort studies also suggested an increased risk of liver cancer in subjects exposed to 
asbestos.110,111 However, most of these studies reported estimates for the broad category of 
liver cancers, without reporting specific data on CCA. There are several reasons behind the 
lack of specific data on CCA. First, iCCA comprises approximately 10-20% of all primary 
liver cancers4,6 therefore, estimated relative risks are driven by the vast majority of HCCs, 
with iCCAs playing a minor role. Secondly, only very large cohorts (e.g., those based on 
nationwide registers) have enough statistical power to study iCCA as a specific disease. 
Recently, a link between asbestos exposure and CCA has been provided in two different 
case-control studies. In the first study, an OR=4.81 (95% CI 1.73–13.33) for iCCA risk was 
reported among subjects occupationally exposed to asbestos for over 30 years; a limited 
evidence was instead reported for eCCA (OR=2.09, 95% CI 0.83-5.27).112 These findings 
have been confirmed in a case-control population-based study on the Nordic Occupational 
Cancer cohort, where an increased risk of iCCA, but not of eCCA, was observed by 
cumulative exposure to asbestos: 0.1–4.9 f/ml x years, OR=1.1 (95% CI 0.9–1.3); 5.0–9.9 
f/ml x years, OR=1.3 (95% CI 0.9–2.1); 10.0–14.9 f/ml x years, OR=1.6 (95% CI 1.0–2.5); 
≥15.0 f/ml x years, OR=1.7 (95% CI 1.1–2.6).113 Overall these findings provide evidence that 
asbestos may represent a risk factor for iCCA. Although how asbestos fibers may reach the 
biliary tract remains an open question, these fibers have been detected in this body region.114 
It can be hypothesized that, after crossing the alveolar barrier after inhalation or penetrating 
the gastrointestinal mucosa after ingestion, they may reach the interstitial environment and 
circulatory system through lymphatic vessels, and finally be delivered to all body districts.115 
In the biliary tract, they could remain trapped in the smaller bile ducts, thus explaining why 
asbestos exposure seems to be mainly involved in iCCA, and not eCCA, pathogenesis. 
Taking into account the number of subjects occupationally or environmentally exposed to 
asbestos, this risk factor is likely one of the most responsible for iCCA increasing incidence 
worldwide. In our case series (G.B) of about 600 CCAs, about 40% of cases were related to 
asbestos exposure (unpublished data). 
Genetic polymorphisms 
Host genetic polymorphisms have been shown to modulate CCA risk. Preliminary evidences 
support an association between CCA and polymorphisms in genes codifying for glutathione 
S-transferases (GSTs). The GSTO1*D140 polymorphism was reported to increase CCA risk
(OR=8.5, CI 95%: 2.07-37.85).116 Similarly, polymorphisms in the carcinogen detoxification
enzymes GSTM1 and GSTT1 have been linked to CCA development. Indeed, ex-regular
alcohol drinkers harbouring the GSTT1-/- genotype were found to associate with a higher
CCA risk compared to those ones harbouring the GSTT1+/+ genotype (OR=27.93, 95% CI
1.84-424.60 vs OR=1.28, 95% CI 0.12, respectively).117 In addition, in anti-O.Viverrini
positive subjects, the GSTM1-/- genotype was found to increase the risk for CCA compared to
GSTM1+/+ genotype (OR=18.00, 95% CI 3.33-97.40 vs OR=10.34, 95% CI 1.31-81.63).117
Another study provided evidence that 1298CC homozygous variants in the 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene (that codifies a pivotal enzyme involved 
in folate metabolism and DNA methylation) may increase the risk of CCA in subjects 
positive for O.Viverrini infection, when compared to wild-type subjects (OR=2.0, 95% CI 
1.14-3.48).118 Polymorphisms in MTHFR gene have been also reported to increase the risk of 
CCA when combined with polymorphisms in thymidylate synthase enhancer region (TSER), 
that competes with MTHFR for 5-methyltetrahydrofolate as substrate for thymidylate 
synthesis. An OR=5.38 (95% CI 1.23-23.56) has been indeed reported in subjects harbouring 
a combination of MTHFR 677CC with the TSER 2R(+) genotype, compared 
to MTHFR 677CC with TSER 2R(-).119  
In patients with PSC, two polymorphisms of the natural killer cell receptor G2D (NKG2D) 
were found to associate with increased CCA risk: the rs11053781 (OR=2.08, 95% CI 1.31-
3.29) and the rs2617167 (OR=2.32, 95% CI 1.47-3.66).120 However, the functional role of 
these polymorphisms on CCA susceptibility still remains to be fully elucidated.  
The multidrug resistance-associated protein 2 (MRP2/ABCC2) is one of the ATP-binding 
cassette (ABC) transporters expressed on the apical membrane of hepatocytes and 
cholangiocytes, and it is involved in the excretion of the conjugates of carcinogens into bile. 
The ABCC2 c.3972T allele has been found to be more frequent in patients with CCA (32%), 
compared to healthy subjects (26.0%), resulting in an OR=1.83 (95% CI 1.09-3.08).121 
Polymorphisms in human oxoguanine glycosylase 1 (hOGG1) and MutY homolog (MUTYH, 
MYH) genes, that codify key proteins in DNA base excision repair pathway, have been also 
linked to CAA. Individuals with A/A genotype in MYHrs3219472 gene have been reported 
to have an increased risk for CCA (OR=2.816, 95% CI 0.992-7.999); conversely, T/G 
genotype in MYH rs3219476 was found to associate with a reduced risk (OR=0.478, 95% CI 
0.17-0.758).122 Another study reported a significant association between hOGG1 and GSTM1 
polymorphisms for the risk for CCA. Indeed, when GSTM1 polymorphism was considered, 
the hOGG1 326 polymorphism was related to the decreased risk for CCA: OR=0.06 (95% CI 
0.01-0.53) for subjects with hOGG1 Ser/Ser and GSTM1 null, OR=0.06 (95% CI 0.01-0.54) 
for subjects with hOGG1 Ser/Cys or Cys/Cys and GSTM1 wild-type and OR=0.14 (95% CI 
0.02-1.08) for subjects with hOGG1 Ser/Cysor Cys/Cys and GSTM1 null, respectively.123 
The aryl-hydrocarbon hydroxylase, a phase I enzyme encoded by the CYP1A1 gene, 
metabolizes exogenous compounds (drugs, tobacco, polycyclic aromatic hydrocarbons, 
nitrosamines and aromatic amines) to carcinogenic intermediates. Among smoker male 
subjects, the CYP1A2*1A/*1A genotype was found to associate with a decreased CCA risk 
(OR=0.28, 95% CI 0.08-0.94), when compared to CYP1A2*1F/1*F.124 Similarly, subjects 
harbouring the alleles NAT2*13, *6B and *7A of the arylamine N-acetyltransferases 
(involved in detoxification of xenobiotics and carcinogens) were associated with a decreased 
CCA risk (OR=0.26, 95%CI 0.15-0.44).124  
Overall these studies suggest that polymorphisms of genes encoding enzymes involved in 
xenobiotic detoxification, DNA repair, multidrug resistance, immune response and folate 
metabolism may be involved in CCA development. However, because of some of these 
studies also included gallbladder and ampullary cancers in their analysis and because of the 
lack of replication in independent cohorts, no definitive conclusions can be drawn. 
COMBINED HCC-iCCA 
Combined hepatocellular-cholangiocarcinoma (CHC) account for between 0.5 to 14% of 
primary liver cancers. 125 They have a mixture of parent phenotypic characteristics and are 
typically even more aggressive than HCC or iCCA.125 Although less well studied, CHCs are 
postulated to arise from hepatic progenitor cells in the canals of Hering. It is perhaps not 
surprising that HCC and iCCA share several chronic risk factors with respect to chronic liver 
disease and its causes. 
CONCLUSIONS 
Multiple risk factors have been associated with CCA, several of which have increased 
globally over the past few decades and may be contributing to rising CCA rates. However, 
most cases develop with any known risk factor and are sporadic. iCCA incidence appears to 
be increasing, although the impact of peri-hilar CCA is unclear, due to lack of clear data on 
sub-types. Asbestos, metabolic syndrome and other emerging risk factors for iCCA may be 
contributing to its increase worldwide. Greater surveillance in subjects exposed to these risk 
factors and thus at higher risk of disease should be considered in the future. Moreover, the 
contribution of host genetic factors to cholangiocarcinogenesis is also currently relatively 
basic compared to several other cancers. There is therefore an ongoing need for further 
studies of the mechanisms underlying malignant transformation in the biliary tree, including 
genetic and basic science studies in addition to epidemiological data to be recorded uniformly 
and accurately. 
Table 1: Global incidence rates of CCA, per 100,000 (100): 






Thailand - North East 85 
Thailand - North and 
Central 
14.5 
Thailand - South 5.7 
China, Shanghai 7.6 
Hong Kong 2.3 
Taiwan 4.7
South Korea, Gwangju 8.8 
South Korea, Busan 7.1 
Japan, Osaka 3.5 




United Kingdom 2.2 











New Zealand 0.4 
Puerto Rico 0.4 
Costa Rica 0.3 
Israel 0.3
Table 2: Risk factors for iCCA and eCCA. 
Risk factor Strength of the association 
in iCCA
Strength of the association 
 in eCCA 
Bile duct cysts ++++ ++++
Caroli’s disease ++++ ++++
PSC/ Cholangitis ++++a ++++a 




Cirrhosis +++/++++ ++/+++ 
HBV ++/+++ +
HCV ++/+++ +/++
Hemochromatosis ++ No association 
Wilson’s disease No association No association 
IBD ++ +/++ 
Chronic pancreatitis ++ +++ 
Duodenal/gastric ulcer + + 
O. viverrini +++a +++a
C. sinensis +++a +++a
Diabete type II  + + 
Obesity +a +a 
NAFLD/NASH +++ ++ 
Alcohol ++ No association
Cigarette smoking + + 
Thorotrast ++++a ++++a 
1,2-dichloropropane ++++a ++++a 
Asbestos +++ +/++
+ = weak/modest association (OR: 1-1.7); ++ = moderate association (OR: 1.7-3); +++ =
strong association (OR: 3-8); ++++ = very strong association (OR> 8)
a Available studies did not distinguish between iCCA and eCCA
Table 3: Classification of Choledochal Cysts23 
Type I The most common variety (80-90%), involving saccular or fusiform dilatation of 
a portion or entire common bile duct (CBD) with normal intrahepatic ducts 
Type II Present as an isolated diverticulum protruding from the CBD 
Type III (or Choledochocele): arise from dilatation of duodenal portion of CBD or where 
pancreatic duct meets 
Type IVa Characterized by multiple dilatations of the intra- and extrahepatic biliary tree 
Type IVb Multiple dilatations involving only the extrahepatic bile ducts 
Type V Cystic dilatation of intrahepatic biliary ducts without extrahepatic duct disease. 
Multiple saccular or cystic dilations of the intrahepatic ducts is also known as 
Caroli's disease 
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